Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia [Cost-utility of dalbavancin in patients with non-severe ABSSSI in Italy]
| Autor: | Rosario Cultrera, Maria Assunta Rotundo, C. Bini, Francesco Saverio Mennini, Andrea Marcellusi |
|---|---|
| Jazyk: | italština |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Standard of care Settore SECS-P/06 03 medical and health sciences 0302 clinical medicine Economica medicine In patient 030212 general & internal medicine 0303 health sciences Cost–utility analysis Staphylococcal skin diseases 030306 microbiology business.industry Health Policy Cost-effectiveness analysis Cost-utility analysis Dalbavancin Cost-effectiveness analysis Cost-utility analysis Dalbavancin Staphylococcal skin diseases Emergency department Cost utility Settore MED/42 Emergency medicine Skin structure business |
| Popis: | Introduction: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibiotic therapies for the management of non-severe ABSSSIs from the National Health Service (NHS) perspective. Methods: A probabilistic decision tree model was developed considering a 30-days follow-up to simulate the therapeutic pathway of a patient treated with dalbavancin or Standard of Care (SoC). The model considered three mutually exclusive health states: a) discharge of patients from the emergency department, b) discharge of patients after one night from admission, c) discharge after 24 or 36 hours from admission. A one-way deterministic sensitivity analysis and a probabilistic sensitivity analysis were conducted. Results: The analysis showed that the use of dalbavancin in patients with non-severe ABSSSI compared to SoC could generate a reduction in costs (– € 291.6 per patient treated) and an increase in QALYs (+0.0018 per patient treated). In 99.7% of the simulations carried out, dalbavancin was dominant compared to the SoC. Considering a threshold for the willingness to pay of € 30,000 for QALY gained, the minimum level of efficacy of dalbavancin so that the treatment can be considered cost-effective compared to the SoC was equal to 69.4%. Conclusions: The analysis showed that dalbavancin may represent a cost-effective option compared to SoC for the treatment of patients with non-severe ABSSSI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|